Literature DB >> 6256771

Distinct cholecystokinin receptors in brain and pancreas.

R B Innis, S H Snyder.   

Abstract

125I-Labeled (Bolton-Hunter) cholecystokinin triacontatriapeptide (CCK-33) binds saturably and reversibly to distinct receptors in brain and pancreatic membranes. The peptide specificity of pancreatic CCK binding is the same as that for pancreatic amylase release. In brain, gastrin and pentagastrin display nanomolar affinity for binding sites, whereas in pancreas these two peptides are virtually inactive. Though these differences indicate that brain and pancreas possess distinct CCK receptors, the two tissues show some similarities. Both pancreas and brain receptors show greater sensitivity to sulfated than to desulfated COOH-terminal octapeptide of CCK and display dissociation constants of 0.3-9.5 nM. The pancreas possesses about 300 times more binding sites than does brain. CCK binding in both brain and pancreas is enhanced by divalent cations and reduced by monovalent cations. Receptor binding in both tissues is regulated in a selective fashion by guanyl nucleotides.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6256771      PMCID: PMC350402          DOI: 10.1073/pnas.77.11.6917

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  New peptide in the vertebrate CNS reacting with antigastrin antibodies.

Authors:  J J Vanderhaeghen; J C Signeau; W Gepts
Journal:  Nature       Date:  1975-10-16       Impact factor: 49.962

2.  alpha-Noradrenergic receptors in the brain: differential effects of sodium on binding of [3H]agonists and [3H]antagonists.

Authors:  D A Greenberg; D C U'Prichard; P Sheehan; S H Snyder
Journal:  Brain Res       Date:  1978-01-27       Impact factor: 3.252

3.  Effects of calcium and chelating agents on the ability of various agonists to increase cyclic GMP in pancreatic acinar cells.

Authors:  R N Lopatin; J D Gardner
Journal:  Biochim Biophys Acta       Date:  1978-11-01

4.  Angiotensin II receptors in bovine adrenal cortex. Modification of angiotensin II binding by guanyl nucleotides.

Authors:  H Glossmann; A Baukal; K J Catt
Journal:  J Biol Chem       Date:  1974-01-25       Impact factor: 5.157

5.  Calcium transport in dispersed acinar cells from rat pancreas.

Authors:  J D Gardner; W F Hahne
Journal:  Biochim Biophys Acta       Date:  1977-12-15

6.  Immunochemical evidence of cholecystokinin-like peptides in brain.

Authors:  G J Dockray
Journal:  Nature       Date:  1976-12-09       Impact factor: 49.962

7.  Immunochemical studies on cholecystokinin. II. Distribution and molecular heterogeneity in the central nervous system and small intestine of man and hog.

Authors:  J F Rehfeld
Journal:  J Biol Chem       Date:  1978-06-10       Impact factor: 5.157

8.  Selective enhancement of [3H]opiate agonist binding by divalent cations.

Authors:  G W Pasternak; A M Snowman; S H Snyder
Journal:  Mol Pharmacol       Date:  1975-11       Impact factor: 4.436

9.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

10.  Cholecystokinin and its COOH-terminal octapeptide in the pig brain.

Authors:  J E Muller; E Straus; R S Yalow
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

View more
  70 in total

1.  Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression.

Authors:  S A Wank; J R Pisegna; A de Weerth
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

2.  Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.

Authors:  V Gigoux; B Maigret; C Escrieut; S Silvente-Poirot; M Bouisson; J A Fehrentz; L Moroder; D Gully; J Martinez; N Vaysse; A D Fourmy
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

3.  CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Paola Moreno; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2015-03-12       Impact factor: 3.444

4.  Characterization of [3H]cholecystokinin octapeptide binding to mouse brain synaptosomes: effects of neuroleptics.

Authors:  Y Hama; M Ebadi
Journal:  Neurochem Res       Date:  1987-08       Impact factor: 3.996

5.  Localization of the murine cholecystokinin A and B receptor genes.

Authors:  L C Samuelson; M S Isakoff; K A Lacourse
Journal:  Mamm Genome       Date:  1995-04       Impact factor: 2.957

6.  Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.

Authors:  L Singh; R J Oles; M J Field; P Atwal; G N Woodruff; J C Hunter
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

7.  [3H]Bradykinin receptor binding in mammalian tissue membranes.

Authors:  R B Innis; D C Manning; J M Stewart; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

8.  Effects of ceruletide and cholecystokinin octapeptide on eating in mice. Interactions with naloxone and the enkephalin analogue, FK 33-824.

Authors:  G Zetler; K H Mörsdorf
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-03       Impact factor: 3.000

9.  Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain.

Authors:  F Noble; M Derrien; B P Roques
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

10.  Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.

Authors:  S J Boyle; K W Tang; G N Woodruff; A T McKnight
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.